{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:dofetilide",
  "owner": "cardio",
  "kind": "drug",
  "slug": "dofetilide",
  "name": "Dofetilide",
  "aliases": [
    "Tikosyn"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Dofetilide, sold as Tikosyn, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug with Vaughan Williams Class III activity; it blocks a potassium current in the heart. The label read lists two uses: the maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than a week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It says the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal. The label carries a boxed warning about induced arrhythmia.",
  "summary_technical": "RxNorm ingredient 49247 (dofetilide, no salt); UNII R4Z9X1N2ND (exact). MeSH has no descriptor for dofetilide (the exact-label descriptor lookup returned an empty list); the term dofetilide exists (T205355) but is not a descriptor, so no MeSH code was added. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic [EPC]). The label read is the Pfizer Laboratories Div Pfizer Inc label for Tikosyn capsules, application NDA020931, effective 2026-04-21 in openFDA. Drugs@FDA also lists a generic product (ANDA210740) whose brand name is a misspelling of dofetilide; generic labels were not read. This page records label indications, the class, the mechanism sentence and the boxed warning only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "49247",
      "normalized_value": "49247",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "R4Z9X1N2ND",
      "normalized_value": "R4Z9X1N2ND",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "arrhythmias"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says dofetilide shows Vaughan Williams Class III antiarrhythmic activity by blocking the cardiac ion channel that carries the rapid component of the delayed rectifier potassium current."
  },
  "content_digest": "717bd69ce8d1e9aa56bb79bc9b5545c4a66467ef33fa76fabceed15d4abd5ebf",
  "review": {
    "content_digest": "717bd69ce8d1e9aa56bb79bc9b5545c4a66467ef33fa76fabceed15d4abd5ebf",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-dofetilide-label-boxed-warning",
      "owner": "cardio",
      "subject_entity_id": "cardio:dofetilide",
      "category": "safety",
      "statement": "The same US label carries a boxed warning about the risk of induced arrhythmia in patients who start or restart the medicine. The warning also names the setting in which treatment is to begin; that instruction is not repeated here.",
      "context": {
        "id": "cardio:ctx-fda-tikosyn-label-boxed-warning",
        "label": "Patients starting or restarting Tikosyn, as described in a US label boxed warning",
        "recipient": "unknown",
        "population": "Patients who are started or restarted on the medicine, as the boxed warning describes them. The passages read give no age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the label passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients initiated or re-initiated on Tikosyn"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records the subject of the label's boxed warning only. The warning goes on to say what prescribers must do when treatment starts or restarts, and the label gives dosing instructions; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], first sentence",
          "applicability_note": "Label passage quoted in the research quote table (LB-11).",
          "snapshot": {
            "id": "cardio:openfda-label-tikosyn-2026-11-18",
            "retrieved_at": "2026-11-18T21:55:13Z",
            "content_hash": "97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3",
            "source_effective_date": "2026-04-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tikosyn",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k26-openfda-label-dofetilide.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260421.",
          "snapshot": {
            "id": "cardio:openfda-label-tikosyn-2026-11-18",
            "retrieved_at": "2026-11-18T21:55:13Z",
            "content_hash": "97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3",
            "source_effective_date": "2026-04-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tikosyn",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k26-openfda-label-dofetilide.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "7ab788aa9dc47078180e75615abb27eeb93fa3b9954d1cc6152bf4a2fb1777db",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-dofetilide-label-boxed-warning.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-dofetilide-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:dofetilide",
      "category": "descriptive",
      "statement": "The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.",
      "context": {
        "id": "cardio:ctx-fda-tikosyn-label-us",
        "label": "Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn",
        "recipient": "unknown",
        "population": "Patients described in the indications section of the label: patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and patients in atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought. The passages read do not state an age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the label passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm",
            "Patients with atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].description[0], first sentence",
          "applicability_note": "Label passage quoted in the research quote table (LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-tikosyn-2026-11-18",
            "retrieved_at": "2026-11-18T21:55:13Z",
            "content_hash": "97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3",
            "source_effective_date": "2026-04-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tikosyn",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k26-openfda-label-dofetilide.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], maintenance of normal sinus rhythm",
          "applicability_note": "Label passage quoted in the research quote table (LB-05, LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-tikosyn-2026-11-18",
            "retrieved_at": "2026-11-18T21:55:13Z",
            "content_hash": "97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3",
            "source_effective_date": "2026-04-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tikosyn",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k26-openfda-label-dofetilide.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], conversion",
          "applicability_note": "Label passage quoted in the research quote table (LB-07, LB-08).",
          "snapshot": {
            "id": "cardio:openfda-label-tikosyn-2026-11-18",
            "retrieved_at": "2026-11-18T21:55:13Z",
            "content_hash": "97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3",
            "source_effective_date": "2026-04-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tikosyn",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k26-openfda-label-dofetilide.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260421.",
          "snapshot": {
            "id": "cardio:openfda-label-tikosyn-2026-11-18",
            "retrieved_at": "2026-11-18T21:55:13Z",
            "content_hash": "97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3",
            "source_effective_date": "2026-04-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-tikosyn",
            "source_type": "regulator",
            "title": "openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k26-openfda-label-dofetilide.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "33109b51794205f8a0c6c954f0bc63fcecd5bf9594a3e74f944615a76ed3cb07",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-dofetilide-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Dofetilide is an antiarrhythmic (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:antiarrhythmic-drugs",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-49247-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[0].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:atrial-fibrillation",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-dofetilide-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:atrial-flutter",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-dofetilide-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/dofetilide/",
  "context_path": "api/v1/context/cardio--dofetilide.md"
}
